Abstract
Introduction: Atopic dermatitis (AD) is a common, chronic, pruritic immune-mediated inflammatory dermatosis. Dupilumab is a fully human IgG4 monoclonal antibody against the interleukin (IL)-4 receptor α (IL-4Rα) subunit and has been recently approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD available in Spain since 2020.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
